Publications

  1. Baranwal A, Langer KJ, Kharfan-Dabaja MA, Ayala E, Foran J, Murthy H, Roy V, Iqbal M, Palmer J, Sproat LZ, Chhabra S, Khera N, Durani U, Hefazi M, Mangaonkar A, Shah MV, Litzow MR, Hogan WJ, Alkhateeb HB. Surrogates of Endothelial Injury Predict Survival After Post-transplant Cyclophosphamide. Transplant Cell Ther. 2024 Aug 16 [Epub ahead of print]
    View PubMed
  2. Ailawadhi S, Adu Y, Frank RD, Das S, Hodge DO, Fernandez A, Flott C, Elliott J, Parrondo R, Sher T, Roy V, Chanan-Khan AA. Factors determining utilization of stem cell transplant for initial therapy of multiple myeloma by patient race: exploring intra-racial healthcare disparities. Blood Cancer J. 2024 May 28; 14 (1):86
    View PubMed
  3. Abdallah N, Witzig TE, Kumar SK, Lacy MQ, Hayman SR, Dispenzieri A, Roy V, Gertz MA, Bergsagel PL, Rajkumar SV. Phase III randomized trial of Thal+ZLD versus ZLD in patients with asymptomatic multiple myeloma - updated results after 18-year follow-up. Leukemia. 2024 May; 38 (5):1169-1171 Epub 2024 Feb 28
    View PubMed
  4. Parrondo RD, Dutta N, LaPlant BR, Elliott J, Fernandez A, Zimmerman A, Cicco G, Han B, Heslop K, Chapin D, Sher T, Roy V, Rasheed A, Das S, Chanan-Khan AA, Paulus A, Ailawadhi S. A phase II study of ibrutinib in combination with ixazomib in patients with Waldenstrom macroglobulinaemia. Br J Haematol. 2024 May; 204 (5):1825-1829 Epub 2024 Jan 29
    View PubMed
  5. Herasevich S, Schulte PJ, Hogan WJ, Alkhateeb H, Zhang Z, White BA, Khera N, Roy V, Gajic O, Yadav H. Lung Injury Prediction Model in Bone Marrow Transplantation: A Multicenter Cohort Study. Am J Respir Crit Care Med. 2024 Mar 1; 209 (5):543-552
    View PubMed
  6. Ames SC, Lange L, Ames GE, Heckman MG, White LJ, Roy V, Foran JM. A prospective study of the relationship between illness perception, depression, anxiety, and quality of life in hematopoietic stem cell transplant patients. Cancer Med. 2024 Feb; 13 (3):e6906 Epub 2024 Jan 11
    View PubMed
  7. Lange LJ, Ames SC, Ames GE, Heckman MG, White LJ, Roy V, Foran JM. Loneliness, immunological recovery patterns, and health-related quality of life (HRQOL) outcomes in patients receiving hematopoietic stem cell transplantation. BMC Psychol. 2024 Jan 19; 12 (1):40
    View PubMed
  8. Alhaj Moustafa M, Parrondo R, Abdulazeez MF, Roy V, Sher T, Alegria VR, Warsame RM, Fonseca R, Rasheed A, Gonsalves WI, Kourelis T, Kapoor P, Buadi FK, Dingli D, Hayman SR, Reeder CB, Chanan-Khan AA, Ailawadhi S. Daratumumab-lenalidomide and daratumumab-pomalidomide in relapsed lenalidomide-exposed or refractory multiple myeloma. Anticancer Drugs. 2024 Jan 1; 35 (1):63-69 Epub 2023 Apr 06
    View PubMed
  9. Yadav U, Kumar SK, Baughn LB, Dispenzieri A, Greipp P, Ketterling R, Jevremovic D, Buadi FK, Dingli D, Lacy MQ, Fonseca R, Bergsagel PL, Ailawadhi S, Roy V, Parrondo R, Sher T, Hayman SR, Kapoor P, Leung N, Cook J, Binder M, Muchtar E, Warsame R, Kourelis TV, Go RS, Lin Y, Seth A, Lester SC, Breen WG, Kyle RA, Gertz MA, Rajkumar SV, Gonsalves WI. Impact of cytogenetic abnormalities on the risk of disease progression in solitary bone plasmacytomas. Blood. 2023 Nov 30; 142 (22):1871-1878
    View PubMed
  10. Das S, Ailawadhi S, Sher T, Roy V, Fernandez A, Parrondo RD. Anti-B Cell Maturation Antigen Chimeric Antigen Receptor T Cell Therapy for the Treatment of AL Amyloidosis and Concurrent Relapsed/Refractory Multiple Myeloma: Preliminary Efficacy and Safety. Curr Oncol. 2023 Oct 31; 30 (11):9627-9633
    View PubMed
  11. Yassine F, Kharfan-Dabaja MA, Tsalantsanis A, Roy V, Zubair AC, Murthy HS, Ayala E, Iqbal M, Sher T, Ailawadhi S, Parrondo RD. Trends in utilization of stored cryopreserved autologous peripheral hematopoietic cells intended for a second (or beyond) autologous hematopoietic cell transplantation in patients with multiple myeloma: a single center experience. Bone Marrow Transplant. 2023 Oct; 58 (10):1130-1136 Epub 2023 July 21
    View PubMed
  12. Ailawadhi S, Ailawadhi M, Dutta N, Parrondo RD, Roy V, Sher T, Baksh M, Rasheed A, Das S, Fernandez AJ, Paulus A, Chanan-Khan AA. The digital divide: Racial disparities in adoption and utilization of health information technology among patients with lymphoid cancers. Cancer Med. 2023 Sep; 12 (18):19013-19020 Epub 2023 Aug 17
    View PubMed
  13. Dhakal B, Zhang MJ, Burns LJ, Tang X, Meyer C, Mau LW, Nooka AK, Stadtmauer E, Micallef IN, McGuirk J, Costa L, Juckett MB, Shah N, Champlin RE, Usmani SZ, Farag SS, Nishihori T, Roy V, Bodiford A, Barnes YJ, Drea EJ, Hari P, Hamadani M. Efficacy, safety, and cost of mobilization strategies in multiple myeloma: a prospective, observational study. Haematologica. 2023 Aug 1; 108(8):2249-2254.
  14. Visram A, Hayman SR, Dispenzieri A, Kapoor P, Lacy MQ, Gertz MA, Buadi FK, Dingli D, Warsame R, Kourelis T, Cook J, Binder M, Gonsalves W, Muchtar E, Leung N, Roy V, Rajkumar SV, Kumar S. A phase 1/2 of carfilzomib and melphalan conditioning for autologous stem cell transplantation for multiple myeloma (CARAMEL). Am J Hematol. 2023 Aug; 98 (8):1277-1285 Epub 2023 June 19
    View PubMed
  15. Kharfan-Dabaja MA, Roy V, Murthy H, Fischer D, Mohty R, Greathouse A, Brown A, Moreno K, Godsey E, Higginbotham JM, Bartholomew A, Jackson A, Torres-Guzman RA, Forte AJ, Ailawadhi S, Dronca R, Maniaci M. Post-Autologous Hematopoietic Cell Transplant Care in the "Home Sweet Home" Setting: A Treatment Paradigm Shift. Hematol Oncol Stem Cell Ther. 2023 May 23; 16 (4):407-411
    View PubMed
  16. Iqbal M, Nieto FAM, Brannick KM, Li Z, Murthy H, Foran J, Roy V, Kharfan-Dabaja MA, Ayala E. A Calcineurin Inhibitor Free Graft Versus Host Disease Prophylaxis for Patients Undergoing Matched Related and Matched Unrelated Donor Allogeneic Hematopoietic Cell Transplant. Transplant Cell Ther. 2023 May; 29 (5):327.e1-327.e9 Epub 2023 Feb 08
    View PubMed
  17. Ailawadhi S, Parrondo RD, Dutta N, Han B, Ciccio G, Cherukuri Y, Alegria VR, LaPlant BR, Roy V, Sher T, Edwards B, Lanier S, Manna A, Heslop K, Caulfield T, Maldosevic E, Storz P, Manochakian R, Asmann Y, Chanan-Khan AA, Paulus A. AT-101 Enhances the Antitumor Activity of Lenalidomide in Patients with Multiple Myeloma. Cancers (Basel). 2023 Jan 12; 15 (2)
    View PubMed
  18. Wolf EB, Li D, Fernandez AJ, Gardner LB, Rivera CE, Wysokinska EM, Shaikh ME, Tun HW, Roy V, Alhaj Moustafa M. Acquired Factor VII Deficiency Associated With Chronic Myeloid Leukemia Blast Crisis. J Investig Med High Impact Case Rep. 2023 Jan-Dec; 11:23247096231209543.
    View PubMed
  19. Ho M, Zanwar S, Buadi FK, Ailawadhi S, Larsen J, Bergsagel L, Binder M, Chanan-Khan A, Dingli D, Dispenzieri A, Fonseca R, Gertz MA, Gonsalves W, Go RS, Hayman S, Kapoor P, Kourelis T, Lacy MQ, Leung N, Lin Y, Muchtar E, Roy V, Sher T, Warsame R, Fonder A, Hobbs M, Hwa YL, Kyle RA, Rajkumar SV, Kumar S. Risk factors for severe infection and mortality In patients with COVID-19 in patients with multiple myeloma and AL amyloidosis. Am J Hematol. 2023 Jan; 98 (1):49-55 Epub 2022 Oct 24
    View PubMed
  20. Ho M, Zanwar S, Buadi FK, Ailawadhi S, Larsen J, Bergsagel L, Binder M, Chanan-Khan AA, Dingli D, Dispenzieri A, Fonseca R, Gertz MA, Gonsalves W, Go RS, Hayman S, Kapoor P, Kourelis T, Lacy MQ, Leung N, Lin Y, Muchtar E, Roy V, Sher T, Warsame R, Fonder A, Hobbs M, Hwa YL, Kyle RA, Rajkumar SV, Kumar S. Risk factors for severe infection and mortality in COVID-19 and monoclonal gammopathy of undetermined significance. Blood. 2022 Nov 3; 140 (18):1997-2000
    View PubMed
  21. Ailawadhi S, Parrondo RD, Moustafa MA, LaPlant BR, Alegria V, Chapin D, Roy V, Sher T, Paulus A, Chanan-Khan AA. Ibrutinib, lenalidomide and dexamethasone in patients with relapsed and/or refractory multiple myeloma: Phase I trial results. Hematol Oncol. 2022 Oct; 40 (4):695-703 Epub 2022 May 08
    View PubMed
  22. Melody M, Gandhi S, Saunders H, Abdel-Rahman Z, Hastings J, Lengerke Diaz P, Gannon N, Truong T, Hathcock M, Khurana A, Johnston P, Ansell S, Bennani N, Paludo J, Bisneto JV, Wang Y, Rosenthal A, Foran J, Ayala E, Murthy HS, Roy V, Castro JE, Lin Y, Kharfan-Dabaja MA. Incidence of thrombosis in relapsed/refractory B-cell lymphoma treated with axicabtagene ciloleucel: Mayo Clinic experience. Leuk Lymphoma. 2022 Jun; 63(6):1363-1368. Epub 2022 Feb 03.
    View PubMed
  23. Griffiths EA, Roy V, Alwan L, Bachiashvili K, Baird J, Cool R, Dinner S, Geyer M, Glaspy J, Gojo I, Hicks A, Kallam A, Kidwai WZ, Kloth DD, Kraut EH, Landsburg D, Lyman GH, Mahajan A, Miller R, Nachar V, Patel S, Patel S, Perez LE, Poust A, Riaz F, Rosovsky R, Rugo HS, Simon S, Vasu S, Wadleigh M, Westbrook K, Westervelt P, Berardi RA, Pluchino L. NCCN Guidelines(R) Insights: Hematopoietic Growth Factors, Version 1.2022. J Natl Compr Canc Netw. 2022 May; 20 (5):436-442
    View PubMed
  24. Ailawadhi S, Swaika A, Advani P, Hodge D, Paulus A, Khera N, Hashmi SK, Alegria VR, Abdulazeez M, Bodepudi S, Jamwal K, Roy V, Sher T, Chanan-Khan A, Ailawadhi M. Awareness of myeloma care and the global impact of treatment: An international internet-based prospective study. J Oncol Pharm Pract. 2022 Mar; 28 (2):425-433 Epub 2021 Mar 09
    View PubMed
  25. Iqbal M, Castano YG, Paludo J, Rosenthal A, Li Z, Beltran M, Moustafa MA, Inwards D, Porrata L, Micallef I, Bisneto JCV, Johnston P, Ansell SM, Reeder C, Murthy H, Roy V, Foran J, Tun HW, Kharfan-Dabaja MA, Ayala E. Impact of Cell of Origin on Outcomes After Autologous Hematopoietic Cell Transplant in Diffuse Large B-Cell Lymphoma. Clin Lymphoma Myeloma Leuk. 2022 Feb; 22 (2):e89-e95 Epub 2021 Aug 31
    View PubMed
  26. Baksh M, Li K, Jiang L, Alegria V, Sher T, Roy V, Chanan-Khan A, Ailawadhi S, Parrondo RD, Alhaj Moustafa M. Myelomatous ascites and pleural effusion in relapsed multiple myeloma. Clin Case Rep. 2022 Feb; 10 (2):e05329 Epub 2022 Feb 02
    View PubMed
  27. Baksh M, Jiang L, Bhatia U, Alegria V, Sher T, Roy V, Chanan-Khan A, Ailawadhi S, Parrondo RD. Management of lytic bone disease in lymphoplasmacytic lymphoma: A case report and review of the literature. Clin Case Rep. 2021 Dec; 9 (12):e05181 Epub 2021 Dec 07
    View PubMed
  28. Bojanini Molina L, Khurana S, Melody M, Jiang L, Roy V. Low-Dose Methotrexate Causing Fatal Pancytopenia in a Patient With Severe Malnutrition. J Clin Rheumatol. 2021 Dec 1; 27 (8S):S764-S765
    View PubMed
  29. Jayakrishnan T, Aulakh S, Baksh M, Nguyen K, Ailawadhi M, Samreen A, Parrondo R, Sher T, Roy V, Manochakian R, Paulus A, Chanan-Khan A, Ailawadhi S. Landmark Cancer Clinical Trials and Real-World Patient Populations: Examining Race and Age Reporting. Cancers (Basel). 2021 Nov 18; 13(22).
    View PubMed
  30. Abdel-Rahman ZH, Heckman MG, Anagnostou T, White LJ, Kloft-Nelson SM, Knudson RA, Alkhateeb HB, Sproat LZ, Khera N, Murthy HS, Ayala E, Hogan WJ, Roy V, Peterson JF, Kharfan-Dabaja MA, Ketterling RP, Litzow MR, Baughn LB, Patnaik M, Greipp PT, Foran JM. Identification of adult Philadelphia-like acute lymphoblastic leukemia using a FISH-based algorithm distinguishes prognostic groups and outcomes. Blood Cancer J 2021 Sep 21; 11 (9):156 Epub 2021 Sept 21
    View PubMed
  31. Abeykoon JP, Zanwar S, Ansell SM, Muchtar E, He R, Greipp PT, King RL, Ailawadhi S, Paludo J, Larsen JT, Habermann TM, Inwards D, Go RS, Thanarajasingam G, Buadi F, Dispenzieri A, Thompson CA, Witzig TE, Lacy M, Gonsalves W, Nowakowski GS, Dingli D, Rajkumar SV, Kyle RA, Sher T, Roy V, Rosenthal A, Chanan-Khan AA, Reeder C, Gertz MA, Kumar S, Kapoor P. Assessment of fixed-duration therapies for treatment-naive Waldenstrom macroglobulinemia. Am J Hematol. 2021 Aug 1; 96 (8):945-953 Epub 2021 May 22
    View PubMed
  32. Melody M, Gandhi S, Rahman ZA, Lengerke-Diaz P, Gannon N, Rosenthal A, Truong T, Novo M, Brandes E, Lange G, Estby B, Johnston P, Ansell S, Bennani NN, Paludo J, Bisneto JV, Ayala E, Tun HW, Murthy HS, Roy V, Foran J, Castro J, Lin Y, Kharfan-Dabaja MA. Impact of hypoalbuminemia on the prognosis of relapsed/refractory B-cell lymphoma treated with axicabtagene ciloleucel. Eur J Haematol. 2021 Jul; 107 (1):48-53 Epub 2021 Apr 15
    View PubMed
  33. Muchtar E, Dispenzieri A, Gertz MA, Kumar SK, Buadi FK, Leung N, Lacy MQ, Dingli D, Ailawadhi S, Bergsagel PL, Fonseca R, Hayman SR, Kapoor P, Grogan M, Abou Ezzeddine OF, Rosenthal JL, Mauermann M, Siddiqui M, Gonsalves WI, Kourelis TV, Larsen JT, Reeder CB, Warsame R, Go RS, Murray DL, McPhail ED, Dasari S, Jevremovic D, Kyle RA, Lin Y, Lust JA, Russell SJ, Hwa YL, Fonder AL, Hobbs MA, Rajkumar SV, Roy V, Sher T. Treatment of AL Amyloidosis: Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Statement 2020 Update. Mayo Clin Proc. 2021 Jun; 96(6):1546-1577.
    View PubMed
  34. Melody M, Rahman ZA, Saunders H, Diaz PL, Gannon N, Rosenthal A, Ayala E, Tun HW, Murthy H, Roy V, Foran J, Castro JE, Guru P, Kharfan-Dabaja MA. C-reactive protein and ferritin levels and length of intensive care unit stay in patients with B-cell lymphomas treated with axicabtagene ciloleucel. Hematol Oncol Stem Cell Ther. 2021 Jun; 14 (2):141-146 Epub 2020 Oct 13
    View PubMed
  35. Parrondo RD, Moustafa MA, Reeder C, Sher T, Roy V, Muchtar E, Warsame R, Alegria V, Gonsalves W, Dingli D, Hayman S, Kapoor P, Chanan-Khan AA, Ailawadhi S. Efficacy of Daratumumab-Based Regimens for the Treatment of Plasma Cell Leukemia. Clin Lymphoma Myeloma Leuk. 2021 May; 21 (5):355-360 Epub 2021 Jan 12
    View PubMed
  36. Kumar V, Ailawadhi M, Dutta N, Abdulazeez M, Aggarwal CS, Quintero G, Baksh M, Roy V, Sher T, Alegria V, Paulus A, Chanan-Khan A, Ailawadhi S. Trends in Early Mortality From Multiple Myeloma: A Population-Based Analysis. Clin Lymphoma Myeloma Leuk. 2021 May; 21 (5):e449-e455 Epub 2020 Dec 24
    View PubMed
  37. Ailawadhi S, Frank R, Ailawadhi M, Kanji Z, Jani P, Fiala M, Abdulazeez M, Ahmed S, Aggarwal CS, Aulakh S, Hodge D, Roy V, Alegria VR, Paulus A, Chanan-Khan A, Sher T. Utilization of radiation therapy in multiple myeloma: trends and changes in practice. Ann Hematol. 2021 Mar; 100 (3):735-741 Epub 2021 Jan 12
    View PubMed
  38. Abdel Rahman ZH, Heckman MG, Miller K, Alkhateeb H, Patnaik MS, Sproat LZ, Jiang L, Roy V, Murthy HS, Ayala E, Hogan WJ, Greipp PT, Kharfan-Dabaja MA, Litzow MR, Foran JM. Impact of Novel Targeted Therapies and Cytogenetic Risk Groups on Outcome After Allogeneic Transplantation for Adult ALL. Transplant Cell Ther. 2021 Feb; 27 (2):165.e1-165.e11 Epub 2020 Dec 11
    View PubMed
  39. Griffiths EA, Alwan LM, Bachiashvili K, Brown A, Cool R, Curtin P, Geyer MB, Gojo I, Kallam A, Kidwai WZ, Kloth DD, Kraut EH, Lyman GH, Mukherjee S, Perez LE, Rosovsky RP, Roy V, Rugo HS, Vasu S, Wadleigh M, Westervelt P, Becker PS. Considerations for use of hematopoietic growth factors in patients With cancer related to the COVID-19 pandemic. JNCCN Journal of the National Comprehensive Cancer Network. 2021; 19 (13):18-21
  40. Iqbal M, Spaulding A, Niazi S, Wood C, Ahmed S, Jani P, Kharfan-Dabaja MA, Ayala E, Manochakian R, Ames S, Paulus A, Ailawadhi S, Roy V, Chanan-Khan A, Sher T. Impact of Depression and Anxiety on Opioid Use in Hospitalized Hematopoietic Cell Transplantation Recipients. Psychosomatics. 2020 Jul - Aug; 61 (4):363-370 Epub 2020 Mar 26
    View PubMed
  41. Kumar V, Alhaj-Moustafa M, Bojanini L, Sher T, Roy V, Manochakian R, Vishnu P, Bodepudi S, Shareef Z, Ahmed S, Jani P, Paulus A, Grover A, Alegria VR, Ailawadhi M, Chanan-Khan A, Ailawadhi S. Timeliness of Initial Therapy in Multiple Myeloma: Trends and Factors Affecting Patient Care. JCO Oncol Pract. 2020 Apr; 16 (4):e341-e349 Epub 2020 Jan 21
    View PubMed
  42. Jain T, Kunze KL, Mountjoy L, Partain DK, Kosiorek H, Khera N, Hogan WJ, Roy V, Slack JL, Noel P, Fauble VDS, Leis JF, Sproat L, Tefferi A, Patnaik MM, Mesa RA, Palmer J. Early post-transplantation factors predict survival outcomes in patients undergoing allogeneic hematopoietic cell transplantation for myelofibrosis. Blood Cancer J. 2020 Mar 10; 10 (3):36
    View PubMed
  43. Parrondo RD, Ailawadhi S, Sher T, Chanan-Khan AA, Roy V. Autologous Stem-Cell Transplantation for Multiple Myeloma in the Era of Novel Therapies. JCO Oncol Pract. 2020 Feb; 16 (2):56-66
    View PubMed
  44. Iqbal M, Reljic T, Ayala E, Sher T, Murthy H, Roy V, Foran J, Tun H, Kumar A, Kharfan-Dabaja MA. Efficacy of Allogeneic Hematopoietic Cell Transplantation in Cutaneous T Cell Lymphoma: Results of a Systematic Review and Meta-Analysis. Biol Blood Marrow Transplant. 2020 Jan; 26 (1):76-82 Epub 2019 Sept 05
    View PubMed
  45. Becker PS, Griffiths EA, Alwan LM, Bachiashvili K, Brown A, Cool R, Curtin P, Dinner S, Gojo I, Hicks A, Kallam A, Kidwai WZ, Kloth DD, Kraut EH, Landsburg D, Lyman GH, Miller R, Mukherjee S, Patel S, Perez LE, Poust A, Rampal R, Rosovsky R, Roy V, Rugo HS, Shayani S, Vasu S, Wadleigh M, Westbrook K, Westervelt P, Burns J, Keller J, Pluchino LA. NCCN Guidelines Insights: Hematopoietic Growth Factors, Version 1.2020. J Natl Compr Canc Netw. 2020 Jan; 18 (1):12-22
    View PubMed
  46. Parrondo RD, Roy V, Sher T, Alegria V, Chanan-Khan AA, Ailawadhi S. Use of KRD-PACE as Salvage Therapy in Aggressive, Relapsed/Bortezomib-Refractory Extramedullary Multiple Myeloma: A Report of Two Cases and Literature Review. Case Rep Hematol. 2020; 2020:4360926 Epub 2020 Feb 18
    View PubMed
  47. Bakeer M, Zubair AC, Roy V. Low baseline platelet count predicts poor response to plerixafor in patients with multiple myeloma undergoing autologous stem cell mobilization. Cytotherapy. 2020 Jan; 22 (1):16-20 Epub 2019 Dec 24
    View PubMed
  48. Becker PS, Griffiths EA, Alwan LM, Bachiashvili K, Brown A, Cool R, Curtin P, Dinner S, Gojo I, Hicks A, Kallam A, Kidwai WZ, Kloth DD, Kraut EH, Landsburg D, Lyman GH, Miller R, Mukherjee S, Patel S, Perez LE, Poust A, Rampal R, Rosovsky R, Roy V, Rugo HS, Shayani S, Vasu S, Wadleigh M, Westbrook K, Westervelt P, Burns J, Keller J, Pluchino LA. Hematopoietic growth factors version 1.2020 featured updates to the nccn guidelines Journal Of The National Comprehensive Cancer Network. 2020 Jan; 18 (1):13-22
  49. Ailawadhi S, Azzouqa AG, Hodge D, Cochuyt J, Jani P, Ahmed S, Sher T, Roy V, Ailawadhi M, Alegria VR, Manochakian R, Vishnu P, Grover A, Abdulazeez MF, Paulus A, Chanan-Khan A. Survival Trends in Young Patients With Multiple Myeloma: A Focus on Racial-Ethnic Minorities. Clin Lymphoma Myeloma Leuk. 2019 Oct; 19 (10):619-623 Epub 2019 June 26
    View PubMed
  50. Kumar V, Ailawadhi S, Bojanini L, Mehta A, Biswas S, Sher T, Roy V, Vishnu P, Marin-Acevedo J, Alegria VR, Paulus A, Aulakh S, Iqbal M, Manochakian R, Tan W, Chanan-Khan A, Ailawadhi M. Trends in the risk of second primary malignancies among survivors of chronic lymphocytic leukemia. Blood Cancer J. 2019 Sep 30; 9 (10):75 Epub 2019 Sept 30
    View PubMed
  51. Torres ME, Hashmi SK, Stevens MA, Tan AD, Callahan V, Sloan JA, Hogan WJ, Litzow MR, Roy V, Foran JM, Colon-Otero G. Impact of hospital hospitality house programs on quality of life and mood of patients and caregivers after hematopoietic stem cell transplant. Hematol Oncol Stem Cell Ther. 2019 Sep; 12 (3):155-160 Epub 2018 Dec 09
    View PubMed
  52. Ailawadhi S, Sher T, Azzouqa AG, Meghji Z, Jain T, Jani P, Ahmed S, Diehl N, Roy V, Shah V, Hodge D, Ailawadhi M, Alegria VR, Paulus A, Chanan-Khan A, Fonseca R. Monoclonal antibody utilization characteristics in patients with multiple myeloma. Anticancer Drugs. 2019 Sep; 30 (8):859-865
    View PubMed
  53. Kumar SK, Berdeja JG, Niesvizky R, Lonial S, Laubach JP, Hamadani M, Stewart AK, Hari P, Roy V, Vescio R, Kaufman JL, Berg D, Liao E, Rajkumar SV, Richardson PG. Ixazomib, lenalidomide, and dexamethasone in patients with newly diagnosed multiple myeloma: long-term follow-up including ixazomib maintenance. Leukemia. 2019 Jul; 33 (7):1736-1746 Epub 2019 Jan 29
    View PubMed
  54. Ailawadhi S, Dholaria BR, Khurana S, Sher T, Alegria V, Paulus A, Ailawadhi M, Mehta A, Chanan-Khan A, Roy V. Outcomes of patients with simultaneous diagnosis of chronic lymphocytic leukaemia/small lymphocytic lymphoma and multiple myeloma. Br J Haematol. 2019 Apr; 185 (2):347-350 Epub 2018 July 05
    View PubMed
  55. Gonsalves WI, Buadi FK, Ailawadhi S, Bergsagel PL, Chanan Khan AA, Dingli D, Dispenzieri A, Fonseca R, Hayman SR, Kapoor P, Kourelis TV, Lacy MQ, Larsen JT, Muchtar E, Reeder CB, Sher T, Stewart AK, Warsame R, Go RS, Kyle RA, Leung N, Lin Y, Lust JA, Russell SJ, Zeldenrust SR, Fonder AL, Hwa YL, Hobbs MA, Mayo AA, Hogan WJ, Rajkumar SV, Kumar SK, Gertz MA, Roy V. Utilization of hematopoietic stem cell transplantation for the treatment of multiple myeloma: a Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus statement. Bone Marrow Transplant. 2019 Mar; 54 (3):353-367 Epub 2018 July 09
    View PubMed
  56. Azzouqa AM, Jouni K, Roy V, Zubair AC. Impact of good and poor mobilizers on hematopoietic progenitor cell collection efficiency and product quality. J Clin Apher. 2019 Feb; 34 (1):39-43 Epub 2018 Nov 14
    View PubMed
  57. Jain T, Kunze KL, Temkit M, Partain DK, Patnaik MS, Slack JL, Khera N, Hogan WJ, Roy V, Noel P, Leis JF, Sproat LZ, Fauble V, Mesa RA, Palmer J. Comparison of reduced intensity conditioning regimens used in patients undergoing hematopoietic stem cell transplantation for myelofibrosis. Bone Marrow Transplant. 2019 Feb; 54 (2):204-211 Epub 2018 May 24
    View PubMed
  58. Khurana S, Beltran M, Jiang L, Ayala E, Roy V. Primary Cutaneous T-Cell Lymphoblastic Lymphoma: Case Report and Literature Review. Case Rep Hematol. 2019; 2019:3540487 Epub 2019 Feb 20
    View PubMed
  59. Dholaria BR, Hammond WA, Roy V, Sher T, Vishnu P, Soyano A, Finn LE, Tun H. Allogeneic hematopoietic cell transplant for relapsed-refractory, marginal zone lymphoma: a single-center experience. Leuk Lymphoma 2018 Nov; 59 (11):2727-2730 Epub 2018 Mar 23
    View PubMed
  60. Paulus A, Manna A, Akhtar S, Paulus SM, Sharma M, Coignet MV, Jiang L, Roy V, Witzig TE, Ansell SM, Allan J, Furman R, Aulakh S, Manochakian R, Ailawadhi S, Chanan-Khan AA, Sher T. Targeting CD38 with daratumumab is lethal to Waldenstrom macroglobulinaemia cells. Br J Haematol. 2018 Oct; 183 (2):196-211 Epub 2018 Aug 06
    View PubMed
  61. Hefazi M, Langer KJ, Khera N, Adamski J, Roy V, Winters JL, Gastineau DA, Jacob EK, Kreuter JD, Gandhi MJ, Hogan WJ, Litzow MR, Hashmi SK, Yadav H, Iyer VN, Scott JP, Wylam ME, Cartin-Ceba R, Patnaik MM. Extracorporeal Photopheresis Improves Survival in Hematopoietic Cell Transplant Patients with Bronchiolitis Obliterans Syndrome without Significantly Impacting Measured Pulmonary Functions. Biol Blood Marrow Transplant. 2018 Sep; 24 (9):1906-1913 Epub 2018 Apr 18
    View PubMed
  62. Niazi S, Frank RD, Sharma M, Roy V, Ames S, Rummans T, Spaulding A, Sher T, Ailawadhi M, Bhatia K, Ahmed S, Tan W, Chanan-Khan A, Ailawadhi S. Impact of psychiatric comorbidities on health care utilization and cost of care in multiple myeloma. Blood Adv. 2018 May 22; 2 (10):1120-1128
    View PubMed
  63. Tefferi A, Partain DK, Palmer JM, Slack JL, Roy V, Hogan WJ, Litzow ML, Ketterling RP, Patnaik MM. Allogeneic hematopoietic stem cell transplant overcomes the adverse survival effect of very high risk and unfavorable karyotype in myelofibrosis. Am J Hematol. 2018 May; 93 (5):649-654 Epub 2018 Feb 24
    View PubMed
  64. Ailawadhi S, Frank RD, Sharma M, Menghani R, Temkit M, Paulus S, Khera N, Hashmi S, Advani P, Swaika A, Paulus A, Aslam N, Sher T, Roy V, Colon-Otero G, Chanan-Khan A. Trends in multiple myeloma presentation, management, cost of care, and outcomes in the Medicare population: A comprehensive look at racial disparities. Cancer. 2018 Apr 15; 124 (8):1710-1721 Epub 2018 Jan 23
    View PubMed
  65. Ailawadhi S, Mikhael JR, LaPlant BR, Laumann KM, Kumar S, Roy V, Dingli D, Bergsagel PL, Buadi FK, Rajkumar SV, Fonseca R, Gertz MA, Kapoor P, Sher T, Hayman SR, Stewart AK, Dispenzieri A, Kyle RA, Gonsalves WI, Reeder CB, Lin Y, Go RS, Leung N, Kourelis T, Lust JA, Russell SJ, Chanan-Khan AA, Lacy MQ. Pomalidomide-dexamethasone in refractory multiple myeloma: long-term follow-up of a multi-cohort phase II clinical trial. Leukemia. 2018 Mar; 32 (3):719-728 Epub 2017 Sept 01
    View PubMed
  66. Ailawadhi S, Frank RD, Advani P, Swaika A, Temkit M, Menghani R, Sharma M, Meghji Z, Paulus S, Khera N, Hashmi SK, Paulus A, Kakar TS, Hodge DO, Colibaseanu DT, Vizzini MR, Roy V, Colon-Otero G, Chanan-Khan AA. Racial disparity in utilization of therapeutic modalities among multiple myeloma patients: a SEER-medicare analysis. Cancer Med. 2017 Dec; 6 (12):2876-2885 Epub 2017 Nov 03
    View PubMed
  67. Crawford J, Becker PS, Armitage JO, Blayney DW, Chavez J, Curtin P, Dinner S, Fynan T, Gojo I, Griffiths EA, Hough S, Kloth DD, Kuter DJ, Lyman GH, Mably M, Mukherjee S, Patel S, Perez LE, Poust A, Rampal R, Roy V, Rugo HS, Saad AA, Schwartzberg LS, Shayani S, Talbott M, Vadhan-Raj S, Vasu S, Wadleigh M, Westervelt P, Burns JL, Pluchino L. Myeloid Growth Factors, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2017 Dec; 15 (12):1520-1541
    View PubMed
  68. Paludo J, Mikhael JR, LaPlant BR, Halvorson AE, Kumar S, Gertz MA, Hayman SR, Buadi FK, Dispenzieri A, Lust JA, Kapoor P, Leung N, Russell SJ, Dingli D, Go RS, Lin Y, Gonsalves WI, Fonseca R, Bergsagel PL, Roy V, Sher T, Chanan-Khan AA, Ailawadhi S, Stewart AK, Reeder CB, Richardson PG, Rajkumar SV, Lacy MQ. Pomalidomide, bortezomib, and dexamethasone for patients with relapsed lenalidomide-refractory multiple myeloma. Blood. 2017 Sep 7; 130 (10):1198-1204 Epub 2017 July 06
    View PubMed
  69. Kapoor P, Ansell SM, Fonseca R, Chanan-Khan A, Kyle RA, Kumar SK, Mikhael JR, Witzig TE, Mauermann M, Dispenzieri A, Ailawadhi S, Stewart AK, Lacy MQ, Thompson CA, Buadi FK, Dingli D, Morice WG, Go RS, Jevremovic D, Sher T, King RL, Braggio E, Novak A, Roy V, Ketterling RP, Greipp PT, Grogan M, Micallef IN, Bergsagel PL, Colgan JP, Leung N, Gonsalves WI, Lin Y, Inwards DJ, Hayman SR, Nowakowski GS, Johnston PB, Russell SJ, Markovic SN, Zeldenrust SR, Hwa YL, Lust JA, Porrata LF, Habermann TM, Rajkumar SV, Gertz MA, Reeder CB. Diagnosis and Management of Waldenstrom Macroglobulinemia: Mayo Stratification of Macroglobulinemia and Risk-Adapted Therapy (mSMART) Guidelines 2016. JAMA Oncol. 2017 Sep 1; 3 (9):1257-1265
    View PubMed
  70. Dingli D, Ailawadhi S, Bergsagel PL, Buadi FK, Dispenzieri A, Fonseca R, Gertz MA, Gonsalves WI, Hayman SR, Kapoor P, Kourelis T, Kumar SK, Kyle RA, Lacy MQ, Leung N, Lin Y, Lust JA, Mikhael JR, Reeder CB, Roy V, Russell SJ, Sher T, Stewart AK, Warsame R, Zeldenrust SR, Rajkumar SV, Chanan Khan AA. Therapy for Relapsed Multiple Myeloma: Guidelines From the Mayo Stratification for Myeloma and Risk-Adapted Therapy. Mayo Clin Proc. 2017 Apr; 92 (4):578-598 Epub 2017 Mar 11
    View PubMed
  71. Kumar SK, LaPlant BR, Reeder CB, Roy V, Halvorson AE, Buadi F, Gertz MA, Bergsagel PL, Dispenzieri A, Thompson MA, Crawley J, Kapoor P, Mikhael J, Stewart K, Hayman SR, Hwa YL, Gonsalves W, Witzig TE, Ailawadhi S, Dingli D, Go RS, Lin Y, Rivera CE, Rajkumar SV, Lacy MQ. Randomized phase 2 trial of ixazomib and dexamethasone in relapsed multiple myeloma not refractory to bortezomib. Blood. 2016 Nov 17; 128 (20):2415-2422 Epub 2016 Oct 04
    View PubMed
  72. Paulus A, Akhtar S, Caulfield TR, Samuel K, Yousaf H, Bashir Y, Paulus SM, Tran D, Hudec R, Cogen D, Jiang J, Edenfield B, Novak A, Ansell SM, Witzig T, Martin P, Coleman M, Roy V, Ailawadhi S, Chitta K, Linder S, Chanan-Khan A. Coinhibition of the deubiquitinating enzymes, USP14 and UCHL5, with VLX1570 is lethal to ibrutinib- or bortezomib-resistant Waldenstrom macroglobulinemia tumor cells. Blood Cancer J. 2016 Nov 4; 6 (11):e492 Epub 2016 Nov 04
    View PubMed
  73. Pawlyn C, Gay F, Larocca A, Roy V, Ailawadhi S. Nuances in the Management of Older People With Multiple Myeloma. Curr Hematol Malig Rep. 2016 Jun; 11 (3):241-51
    View PubMed
  74. Dholaria BR, Cappel M, Roy V. Necrobiotic xanthogranuloma associated with monoclonal gammopathy: successful treatment with lenalidomide and dexamethasone. Ann Hematol 2016 Mar; 95 (4):671-2 Epub 2016 Jan 27
    View PubMed
  75. Barba P, Burns LJ, Litzow MR, Juckett MB, Komanduri KV, Lee SJ, Devlin SM, Costa LJ, Khan S, King A, Klein A, Krishnan A, Malone A, Mir M, Moravec C, Selby G, Roy V, Cochran M, Stricherz MK, Westmoreland MD, Perales MA, Wood WA. Success of an International Learning Health Care System in Hematopoietic Cell Transplantation: The American Society of Blood and Marrow Transplantation Clinical Case Forum. Biol Blood Marrow Transplant. 2016 Mar; 22 (3):564-570 Epub 2015 Dec 21
    View PubMed
  76. Ailawadhi S, Advani P, Yang D, Ghosh R, Swaika A, Roy V, Foran J, Colon-Otero G, Chanan-Khan A. Impact of access to NCI- and NCCN-designated cancer centers on outcomes for multiple myeloma patients: A SEER registry analysis. Cancer. 2016 Feb 15; 122 (4):618-25 Epub 2015 Nov 13
    View PubMed
  77. Kumar SK, Krishnan A, LaPlant B, Laumann K, Roy V, Zimmerman T, Gertz MA, Buadi FK, Stockerl Goldstein K, Birgin A, Fiala M, Duarte L, Maharaj M, Levy J, Vij R. Bendamustine, lenalidomide, and dexamethasone (BRD) is highly effective with durable responses in relapsed multiple myeloma. Am J Hematol. 2015 Dec; 90 (12):1106-10 Epub 2015 Oct 06
    View PubMed
  78. Gupta E, Finn L, Johns G, Pruthi RK, Roy V. Correction of factor XI deficiency by liver transplantation. Blood Coagul Fibrinolysis. 2015 Dec; 26: (8)961-3.
    View PubMed
  79. Kumar SK, LaPlant B, Roy V, Reeder CB, Lacy MQ, Gertz MA, Laumann K, Thompson MA, Witzig TE, Buadi FK, Rivera CE, Mikhael JR, Bergsagel PL, Kapoor P, Hwa L, Fonseca R, Stewart AK, Chanan-Khan A, Rajkumar SV, Dispenzieri A. Phase 2 trial of ixazomib in patients with relapsed multiple myeloma not refractory to bortezomib. Blood Cancer J. 2015 Aug 14; 5:e338
    View PubMed
  80. Dispenzieri A, Buadi F, Kumar SK, Reeder CB, Sher T, Lacy MQ, Kyle RA, Mikhael JR, Roy V, Leung N, Grogan M, Kapoor P, Lust JA, Dingli D, Go RS, Hwa YL, Hayman SR, Fonseca R, Ailawadhi S, Bergsagel PL, Chanan-Khan A, Rajkumar SV, Russell SJ, Stewart K, Zeldenrust SR, Gertz MA. Treatment of Immunoglobulin Light Chain Amyloidosis: Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Statement. Mayo Clin Proc. 2015 Aug; 90(8):1054-81.
    View PubMed
  81. Russell A, Malik S, Litzow M, Gastineau D, Roy V, Zubair AC. Dual roles of autologous CD8+ T cells in hematopoietic progenitor cell mobilization and engraftment. Transfusion. 2015 Jul; 55(7):1758-65; quiz 1757. Epub 2015 Mar 11.
    View PubMed
  82. Vij R, Kumar S, Zhang MJ, Zhong X, Huang J, Dispenzieri A, Abidi MH, Bird JM, Freytes CO, Gale RP, Kindwall-Keller TL, Kyle RA, Landsburg DJ, Lazarus HM, Munker R, Roy V, Sharma M, Vogl DT, Wirk B, Hari PN. Impact of pretransplant therapy and depth of disease response before autologous transplantation for multiple myeloma. Biol Blood Marrow Transplant. 2015 Feb; 21 (2):335-41 Epub 2014 Nov 01
    View PubMed
  83. Kumar SK, LaPlant B, Chng WJ, Zonder J, Callander N, Fonseca R, Fruth B, Roy V, Erlichman C, Stewart AK, Mayo Phase 2 Consortium. Dinaciclib, a novel CDK inhibitor, demonstrates encouraging single-agent activity in patients with relapsed multiple myeloma. Blood. 2015 Jan 15; 125 (3):443-8 Epub 2014 Nov 13
    View PubMed
  84. Kumar SK, Berdeja JG, Niesvizky R, Lonial S, Laubach JP, Hamadani M, Stewart AK, Hari P, Roy V, Vescio R, Kaufman JL, Berg D, Liao E, Di Bacco A, Estevam J, Gupta N, Hui AM, Rajkumar V, Richardson PG, Rajkumar V. Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma: an open-label phase 1/2 study. Lancet Oncol. 2014 Dec; 15 (13):1503-1512 Epub 2014 Nov 14
    View PubMed
  85. Sharma M, Zhang MJ, Zhong X, Abidi MH, Akpek G, Bacher U, Callander NS, Dispenzieri A, Freytes CO, Fung HC, Gale RP, Gasparetto C, Gibson J, Holmberg LA, Kindwall-Keller TL, Klumpp TR, Krishnan AY, Landau HJ, Lazarus HM, Lonial S, Maiolino A, Marks DI, Mehta P, Mikhael Med JR, Nishihori T, Olsson R, Ramanathan M, Roy V, Savani BN, Schouten HC, Scott E, Tay J, To LB, Vesole DH, Vogl DT, Hari P. Older patients with myeloma derive similar benefit from autologous transplantation. Biol Blood Marrow Transplant. 2014 Nov; 20 (11):1796-803 Epub 2014 July 18
    View PubMed
  86. Khera N, Chang YH, Hashmi S, Slack J, Beebe T, Roy V, Noel P, Fauble V, Sproat L, Tilburt J, Leis JF, Mikhael J. Financial burden in recipients of allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2014 Sep; 20 (9):1375-81 Epub 2014 May 24
    View PubMed
  87. Paulus A, Masood A, Miller KC, Khan AN, Akhtar D, Advani P, Foran J, Rivera C, Roy V, Colon-Otero G, Chitta K, Chanan-Khan A. The investigational agent MLN2238 induces apoptosis and is cytotoxic to CLL cells in vitro, as a single agent and in combination with other drugs. Br J Haematol. 2014 Apr; 165: (1)78-88.
    View PubMed
  88. Paulus A, Chitta K, Akhtar S, Personett D, Miller KC, Thompson KJ, Carr J, Kumar S, Roy V, Ansell SM, Mikhael JR, Dispenzieri A, Reeder CB, Rivera CE, Foran J, Chanan-Khan A. AT-101 downregulates BCL2 and MCL1 and potentiates the cytotoxic effects of lenalidomide and dexamethasone in preclinical models of multiple myeloma and Waldenstrom macroglobulinaemia. Br J Haematol. 2014 Feb; 164 (3):352-365 Epub 2013 Nov 17
    View PubMed
  89. Dispenzieri A, Stewart AK, Chanan-Khan A, Rajkumar SV, Kyle RA, Fonseca R, Kapoor P, Bergsagel PL, McCurdy A, Gertz MA, Lacy MQ, Lust JA, Russell SJ, Zeldenrust SR, Reeder C, Roy V, Buadi F, Dingli D, Hayman SR, Leung N, Lin Y, Mikhael J, Kumar SK. Smoldering multiple myeloma requiring treatment: time for a new definition? Blood. 2013 Dec 19; 122 (26):4172-81 Epub 2013 Oct 21
    View PubMed
  90. Copelan EA, Hamilton BK, Avalos B, Ahn KW, Bolwell BJ, Zhu X, Aljurf M, van Besien K, Bredeson C, Cahn JY, Costa LJ, de Lima M, Gale RP, Hale GA, Halter J, Hamadani M, Inamoto Y, Kamble RT, Litzow MR, Loren AW, Marks DI, Olavarria E, Roy V, Sabloff M, Savani BN, Seftel M, Schouten HC, Ustun C, Waller EK, Weisdorf DJ, Wirk B, Horowitz MM, Arora M, Szer J, Cortes J, Kalaycio ME, Maziarz RT, Saber W. Better leukemia-free and overall survival in AML in first remission following cyclophosphamide in combination with busulfan compared with TBI. Blood. 2013 Dec 5; 122(24):3863-70. Epub 2013 Sep 24.
    View PubMed
  91. Roy V, Pockaj BA, Allred JB, Apsey H, Northfelt DW, Nikcevich D, Mattar B, Perez EA. A Phase II trial of docetaxel and carboplatin administered every 2 weeks as preoperative therapy for stage II or III breast cancer: NCCTG study N0338. Am J Clin Oncol. 2013 Dec; 36 (6):540-4
    View PubMed
  92. Larsen JT, Hogan WJ, Micallef IN, Dispenzieri A, Gertz MA, Inwards DJ, Tun HW, Roy V, Geyer SM, Allred JB, Wu W, Ansell SM, Elliott MA, Tefferi A, Porrata LF, Gastineau DA, Lacy MQ, Litzow MR. A phase I/II trial of reduced intensity allogeneic hematopoietic cell transplant for hematologic malignancies using cladribine, thiotepa and rabbit antithymocyte globulin. Leuk Lymphoma. 2013 Aug; 54 (8):1713-8 Epub 2012 Dec 31
    View PubMed
  93. Michaelis LC, Saad A, Zhong X, Le-Rademacher J, Freytes CO, Marks DI, Lazarus HM, Bird JM, Holmberg L, Kamble RT, Kumar S, Lill M, Meehan KR, Saber W, Schriber J, Tay J, Vogl DT, Wirk B, Savani BN, Gale RP, Vesole DH, Schiller GJ, Abidi M, Anderson KC, Nishihori T, Kalaycio ME, Vose JM, Moreb JS, Drobyski W, Munker R, Roy V, Ghobadi A, Holland HK, Nath R, To LB, Maiolino A, Kassim AA, Giralt SA, Landau H, Schouten HC, Maziarz RT, Mikhael J, Kindwall-Keller T, Stiff PJ, Gibson J, Lonial S, Krishnan A, Dispenzieri A, Hari P, Plasma Cell Disorders Working Committee of the Center for International Blood and Marrow Transplant Research. Salvage second hematopoietic cell transplantation in myeloma. Biol Blood Marrow Transplant. 2013 May; 19: (5)760-6.
    View PubMed
  94. Mikhael JR, Dingli D, Roy V, Reeder CB, Buadi FK, Hayman SR, Dispenzieri A, Fonseca R, Sher T, Kyle RA, Lin Y, Russell SJ, Kumar S, Bergsagel PL, Zeldenrust SR, Leung N, Drake MT, Kapoor P, Ansell SM, Witzig TE, Lust JA, Dalton RJ, Gertz MA, Stewart AK, Rajkumar SV, Chanan-Khan A, Lacy MQ, Mayo Clinic. Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines 2013. Mayo Clin Proc. 2013 Apr; 88 (4):360-76
    View PubMed
  95. Andhavarapu S, Roy V. Immunomodulatory drugs in multiple myeloma. Expert Rev Hematol. 2013 Feb; 6(1):69-82.
    View PubMed
  96. Witzig TE, Laumann KM, Lacy MQ, Hayman SR, Dispenzieri A, Kumar S, Reeder CB, Roy V, Lust JA, Gertz MA, Greipp PR, Hassoun H, Mandrekar SJ, Rajkumar SV. A phase III randomized trial of thalidomide plus zoledronic acid versus zoledronic acid alone in patients with asymptomatic multiple myeloma. Leukemia. 2013 Jan; 27 (1):220-5 Epub 2012 Aug 20
    View PubMed
  97. Sluzevich JC, Hall MR, Roy V. Subcutaneous panniculitis-like T-cell lymphoma after rituximab. J Am Acad Dermatol 2012 Nov; 67 (5):e223-5
    View PubMed
  98. Dispenzieri A, Buadi F, Laumann K, LaPlant B, Hayman SR, Kumar SK, Dingli D, Zeldenrust SR, Mikhael JR, Hall R, Rajkumar SV, Reeder C, Fonseca R, Bergsagel PL, Stewart AK, Roy V, Witzig TE, Lust JA, Russell SJ, Gertz MA, Lacy MQ. Activity of pomalidomide in patients with immunoglobulin light-chain amyloidosis. Blood. 2012 Jun 7; 119 (23):5397-404 Epub 2012 Apr 04
    View PubMed
  99. Kumar SK, Hayman SR, Buadi FK, Roy V, Lacy MQ, Gertz MA, Allred J, Laumann KM, Bergsagel LP, Dingli D, Mikhael JR, Reeder CB, Stewart AK, Zeldenrust SR, Greipp PR, Lust JA, Fonseca R, Russell SJ, Rajkumar SV, Dispenzieri A. Lenalidomide, cyclophosphamide, and dexamethasone (CRd) for light-chain amyloidosis: long-term results from a phase 2 trial. Blood. 2012 May 24; 119 (21):4860-7 Epub 2012 Apr 13
    View PubMed
  100. Jiang L, Malik S, Litzow M, Gastineau D, Micallef I, Roy V, Solberg L, Zubair AC. Hematopoietic stem cells from poor and good mobilizers are qualitatively equivalent. Transfusion. 2012 Mar; 52 (3):542-8 Epub 2011 Aug 09
    View PubMed
  101. Gertz MA, Buadi FK, Hayman SR, Dingli D, Dispenzieri A, Greipp PR, Kumar SK, Lacy MQ, Lust JA, Leung N, Rajkumar SV, Russell SJ, Zeldenrust SR, Mikhael JR, Roy V, Kyle RA. Immunoglobulin D amyloidosis: a distinct entity. Blood. 2012 Jan 5; 119 (1):44-8 Epub 2011 Nov 07
    View PubMed
  102. Roy V. Autologous stem cell transplant for Al amyloidosis. Bone Marrow Res. 2012; 2012:238961 Epub 2012 May 16
    View PubMed
  103. Vishnu P, Roy V, Paulsen A, Zubair AC. Efficacy and cost-benefit analysis of risk-adaptive use of plerixafor for autologous hematopoietic progenitor cell mobilization. Transfusion. 2012 Jan; 52 (1):55-62 Epub 2011 June 09
    View PubMed
  104. Vogl DT, Wang T, Perez WS, Stadtmauer EA, Heitjan DF, Lazarus HM, Kyle RA, Kamble R, Weisdorf D, Roy V, Gibson J, Ballen K, Holmberg L, Bashey A, McCarthy PL, Freytes C, Maharaj D, Maiolino A, Vesole D, Hari P. Effect of obesity on outcomes after autologous hematopoietic stem cell transplantation for multiple myeloma. Biol Blood Marrow Transplant. 2011 Dec; 17(12):1765-74. Epub 2011 May 11.
    View PubMed
  105. Reinholz MM, Kitzmann KA, Tenner K, Hillman D, Dueck AC, Hobday TJ, Northfelt DW, Moreno-Aspitia A, Roy V, LaPlant B, Allred JB, Stella PJ, Lingle WL, Perez EA. Cytokeratin-19 and mammaglobin gene expression in circulating tumor cells from metastatic breast cancer patients enrolled in North Central Cancer Treatment Group trials, N0234/336/436/437. Clin Cancer Res. 2011 Nov 15; 17 (22):7183-93 Epub 2011 Oct 05
    View PubMed
  106. Lacy MQ, Allred JB, Gertz MA, Hayman SR, Short KD, Buadi F, Dispenzieri A, Kumar S, Greipp PR, Lust JA, Russell SJ, Dingli D, Zeldenrust S, Fonseca R, Bergsagel PL, Roy V, Stewart AK, Laumann K, Mandrekar SJ, Reeder C, Rajkumar SV, Mikhael JR. Pomalidomide plus low-dose dexamethasone in myeloma refractory to both bortezomib and lenalidomide: comparison of 2 dosing strategies in dual-refractory disease. Blood. 2011 Sep 15; 118 (11):2970-5 Epub 2011 June 20
    View PubMed
  107. Short KD, Rajkumar SV, Larson D, Buadi F, Hayman S, Dispenzieri A, Gertz M, Kumar S, Mikhael J, Roy V, Kyle RA, Lacy MQ. Incidence of extramedullary disease in patients with multiple myeloma in the era of novel therapy, and the activity of pomalidomide on extramedullary myeloma. Leukemia. 2011 Jun; 25 (6):906-8 Epub 2011 Feb 25
    View PubMed
  108. Adkisson CD, Vallow LA, Kowalchik K, McNeil R, Hines S, Deperi E, Moreno A, Roy V, Perez EA, McLaughlin SA. Patient age and preoperative breast MRI in women with breast cancer: biopsy and surgical implications. Ann Surg Oncol. 2011 Jun; 18(6):1678-83. Epub 2011 Jan 05.
    View PubMed
  109. Kapoor P, Rajkumar SV, Dispenzieri A, Gertz MA, Lacy MQ, Dingli D, Mikhael JR, Roy V, Kyle RA, Greipp PR, Kumar S, Mandrekar SJ. Melphalan and prednisone versus melphalan, prednisone and thalidomide for elderly and/or transplant ineligible patients with multiple myeloma: a meta-analysis. Leukemia. 2011 Apr; 25(4):689-96. Epub 2011 Jan 14.
    View PubMed
  110. Vishnu P, Roy V. Safety and Efficacy of nab-Paclitaxel in the Treatment of Patients with Breast Cancer. Breast Cancer (Auckl). 2011; 5:53-65 Epub 2011 Apr 13
    View PubMed
  111. Reece DE, Vesole DH, Shrestha S, Zhang MJ, Perez WS, Dispenzieri A, Milone GA, Abidi M, Atkins H, Bashey A, Bredeson CN, Boza WB, Freytes CO, Gale RP, Gajewski JL, Gibson J, Hale GA, Kumar S, Kyle RA, Lazarus HM, McCarthy PL, Pavlovsky S, Roy V, Weisdorf DJ, Wiernik PH, Hari PN. Outcome of patients with IgD and IgM multiple myeloma undergoing autologous hematopoietic stem cell transplantation: a retrospective CIBMTR study. Clin Lymphoma Myeloma Leuk. 2010 Dec; 10(6):458-63.
    View PubMed
  112. Dispenzieri A, Abraham M, Hayman SR, Buadi F, Kumar S, Reeder CB, Mikhael JR, Zeldenrust S, Rajkumar SV, Short KD, Greipp PR, Russell SJ, Dingli D, Allred J, Laumann K, Fonseca R, Bergsagel PL, Roy V, Stewart K, Lacy M. A phase-2 study of pomalidomide and dexamethasone in previously treated light chain (AL) amyloidosis. Blood. 2010 Nov 19; 116(21):434-5.
  113. Lacy MQ, Hayman SR, Gertz MA, Short KD, Dispenzieri A, Kumar S, Greipp PR, Lust JA, Russell SJ, Dingli D, Zeldenrust S, Fonseca R, Bergsagel PL, Roy V, Mikhael JR, Stewart AK, Laumann K, Allred JB, Mandrekar SJ, Rajkumar SV, Buadi F. Pomalidomide (CC4047) plus low dose dexamethasone (Pom/dex) is active and well tolerated in lenalidomide refractory multiple myeloma (MM). Leukemia. 2010 Nov; 24 (11):1934-9 Epub 2010 Sept 09
    View PubMed
  114. Bhatt V, Vendrell N, Nau K, Crumb D, Roy V. Implementation of a standardized protocol for prevention and management of oral mucositis in patients undergoing hematopoietic cell transplantation. J Oncol Pharm Pract. 2010 Sep; 16 (3):195-204 Epub 2009 Nov 12
    View PubMed
  115. Ansell SM, Kyle RA, Reeder CB, Fonseca R, Mikhael JR, Morice WG, Bergsagel PL, Buadi FK, Colgan JP, Dingli D, Dispenzieri A, Greipp PR, Habermann TM, Hayman SR, Inwards DJ, Johnston PB, Kumar SK, Lacy MQ, Lust JA, Markovic SN, Micallef IN, Nowakowski GS, Porrata LF, Roy V, Russell SJ, Short KE, Stewart AK, Thompson CA, Witzig TE, Zeldenrust SR, Dalton RJ, Rajkumar SV, Gertz MA. Diagnosis and management of Waldenstrom macroglobulinemia: Mayo stratification of macroglobulinemia and risk-adapted therapy (mSMART) guidelines. Mayo Clin Proc. 2010 Sep; 85 (9):824-33 Epub 2010 Aug 11
    View PubMed
  116. Gay F, Rajkumar SV, Coleman M, Kumar S, Mark T, Dispenzieri A, Pearse R, Gertz MA, Leonard J, Lacy MQ, Chen-Kiang S, Roy V, Jayabalan DS, Lust JA, Witzig TE, Fonseca R, Kyle RA, Greipp PR, Stewart AK, Niesvizky R. Clarithromycin (Biaxin)-lenalidomide-low-dose dexamethasone (BiRd) versus lenalidomide-low-dose dexamethasone (Rd) for newly diagnosed myeloma. Am J Hematol. 2010 Sep; 85 (9):664-9
    View PubMed
  117. Vishnu P, Roy V. nab-paclitaxel: a novel formulation of taxane for treatment of breast cancer. Womens Health (Lond). 2010 Jul; 6 (4):495-506
    View PubMed
  118. Johnston PB, Inwards DJ, Colgan JP, Laplant BR, Kabat BF, Habermann TM, Micallef IN, Porrata LF, Ansell SM, Reeder CB, Roy V, Witzig TE. A Phase II trial of the oral mTOR inhibitor everolimus in relapsed Hodgkin lymphoma. Am J Hematol. 2010 May; 85 (5):320-4
    View PubMed
  119. Ballen KK, Shrestha S, Sobocinski KA, Zhang MJ, Bashey A, Bolwell BJ, Cervantes F, Devine SM, Gale RP, Gupta V, Hahn TE, Hogan WJ, Kroger N, Litzow MR, Marks DI, Maziarz RT, McCarthy PL, Schiller G, Schouten HC, Roy V, Wiernik PH, Horowitz MM, Giralt SA, Arora M. Outcome of transplantation for myelofibrosis. Biol Blood Marrow Transplant. 2010 Mar; 16(3):358-67. Epub 2009 Oct 30.
    View PubMed
  120. Gay F, Hayman SR, Lacy MQ, Buadi F, Gertz MA, Kumar S, Dispenzieri A, Mikhael JR, Bergsagel PL, Dingli D, Reeder CB, Lust JA, Russell SJ, Roy V, Zeldenrust SR, Witzig TE, Fonseca R, Kyle RA, Greipp PR, Stewart AK, Rajkumar SV. Lenalidomide plus dexamethasone versus thalidomide plus dexamethasone in newly diagnosed multiple myeloma: a comparative analysis of 411 patients. Blood. 2010 Feb 18; 115 (7):1343-50 Epub 2009 Dec 11
    View PubMed
  121. Kumar SK, Mikhael JR, Buadi FK, Dingli D, Dispenzieri A, Fonseca R, Gertz MA, Greipp PR, Hayman SR, Kyle RA, Lacy MQ, Lust JA, Reeder CB, Roy V, Russell SJ, Short KE, Stewart AK, Witzig TE, Zeldenrust SR, Dalton RJ, Rajkumar SV, Bergsagel PL. Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines. Mayo Clin Proc 2009 Dec; 84 (12):1095-110
    View PubMed
  122. Dispenzieri A, Gertz MA, Hayman SR, Buadi F, Kumar S, Reeder CB, Zeldenrust SR, Rajkumar SV, Detweiler-Short K, Lust JA, Witzig TE, Greipp PR, Russell SJ, Dingli D, Allred J, Laumann K, Thompson MA, Fonseca R, Stewart AK, Bergsagel PL, Mikhael JR, Roy V, Kyle R, Lacy MQ. A pilot study of pomalidomide and dexamethasone in previously treated light chain amyloidosis patients. Blood. 2009 Nov 20; 114(22):1482-3.
  123. Roy V, Perez EA. Beyond trastuzumab: small molecule tyrosine kinase inhibitors in HER-2-positive breast cancer. Oncologist. 2009 Nov; 14 (11):1061-9 Epub 2009 Nov 03
    View PubMed
  124. Lacy MQ, Hayman SR, Gertz MA, Dispenzieri A, Buadi F, Kumar S, Greipp PR, Lust JA, Russell SJ, Dingli D, Kyle RA, Fonseca R, Bergsagel PL, Roy V, Mikhael JR, Stewart AK, Laumann K, Allred JB, Mandrekar SJ, Rajkumar SV. Pomalidomide (CC4047) plus low-dose dexamethasone as therapy for relapsed multiple myeloma. J Clin Oncol. 2009 Oct 20; 27 (30):5008-14 Epub 2009 Aug 31
    View PubMed
  125. Schaefer EW, Loaiza-Bonilla A, Juckett M, DiPersio JF, Roy V, Slack J, Wu W, Laumann K, Espinoza-Delgado I, Gore SD, Mayo P2C Phase II Consortium. A phase 2 study of vorinostat in acute myeloid leukemia. Haematologica. 2009 Oct; 94 (10):1375-82
    View PubMed
  126. Hari PN, Zhang MJ, Roy V, Perez WS, Bashey A, To LB, Elfenbein G, Freytes CO, Gale RP, Gibson J, Kyle RA, Lazarus HM, McCarthy PL, Milone GA, Pavlovsky S, Reece DE, Schiller G, Vela-Ojeda J, Weisdorf D, Vesole D. Is the International Staging System superior to the Durie-Salmon staging system? A comparison in multiple myeloma patients undergoing autologous transplant. Leukemia. 2009 Aug; 23(8):1528-34. Epub 2009 Mar 26.
    View PubMed
  127. Kapoor P, Kumar S, Fonseca R, Lacy MQ, Witzig TE, Hayman SR, Dispenzieri A, Buadi F, Bergsagel PL, Gertz MA, Dalton RJ, Mikhael JR, Dingli D, Reeder CB, Lust JA, Russell SJ, Roy V, Zeldenrust SR, Stewart AK, Kyle RA, Greipp PR, Rajkumar SV. Impact of risk stratification on outcome among patients with multiple myeloma receiving initial therapy with lenalidomide and dexamethasone. Blood. 2009 Jul 16; 114 (3):518-21 Epub 2009 Mar 26
    View PubMed
  128. Roy V, Perez EA. Biologic therapy of breast cancer: focus on co-inhibition of endocrine and angiogenesis pathways. Breast Cancer Res Treat. 2009 Jul; 116(1):31-8. Epub 2008 Dec 20.
    View PubMed
  129. Amar S, Roy V, Perez EA. Treatment of metastatic breast cancer: looking towards the future. Breast Cancer Res Treat. 2009 Apr; 114 (3):413-22 Epub 2008 May 09
    View PubMed
  130. Roy V, LaPlant BR, Gross GG, Bane CL, Palmieri FM, North Central Cancer Treatment Group. Phase II trial of weekly nab (nanoparticle albumin-bound)-paclitaxel (nab-paclitaxel) (Abraxane) in combination with gemcitabine in patients with metastatic breast cancer (N0531). Ann Oncol. 2009 Mar; 20 (3):449-53 Epub 2008 Dec 15
    View PubMed
  131. Roy V. Artifactual laboratory abnormalities in patients with paraproteinemia. South Med J. 2009 Feb; 102(2):167-70.
    View PubMed
  132. Zubair AC, Grant R, Wu W, Tun H, Rivera C, Moreno-Aspitia A, Joyce M, Roy V, Colon-Otero G, Solberg LA. Platelet count is a sensitive predictor of autologous peripheral blood progenitor cell collection yield in previously treated plasma cell disease patients. Transfusion. 2008 Jun; 48 (6):1106-14 Epub 2008 Feb 25
    View PubMed
  133. Kumar S, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, Gastineau DA, Litzow MR, Fonseca R, Roy V, Rajkumar SV, Gertz MA. Impact of lenalidomide therapy on stem cell mobilization and engraftment post-peripheral blood stem cell transplantation in patients with newly diagnosed myeloma. Leukemia. 2007 Sep; 21 (9):2035-42 Epub 2007 June 21
    View PubMed
  134. Amar S, Roy V, Perez EA. Letrozole: present and future role in the treatment of breast cancer. Expert Opin Pharmacother. 2007 Aug; 8(12):1965-75.
    View PubMed
  135. Stewart AK, Bergsagel PL, Greipp PR, Dispenzieri A, Gertz MA, Hayman SR, Kumar S, Lacy MQ, Lust JA, Russell SJ, Witzig TE, Zeldenrust SR, Dingli D, Reeder CB, Roy V, Kyle RA, Rajkumar SV, Fonseca R. A practical guide to defining high-risk myeloma for clinical trials, patient counseling and choice of therapy. Leukemia. 2007 Mar; 21(3):529-34. Epub 2007 Jan 18.
    View PubMed
  136. Dispenzieri A, Rajkumar SV, Gertz MA, Fonseca R, Lacy MQ, Bergsagel PL, Kyle RA, Greipp PR, Witzig TE, Reeder CB, Lust JA, Russell SJ, Hayman SR, Roy V, Kumar S, Zeldenrust SR, Dalton RJ, Stewart AK. Treatment of newly diagnosed multiple myeloma based on Mayo Stratification of Myeloma and Risk-adapted Therapy (mSMART): consensus statement. Mayo Clin Proc. 2007 Mar; 82: (3)323-41.
    View PubMed
  137. Roy A, Roy V. An unusual case of prochlorperazine induced dyskinesia masquerading as stroke. Resident & Staff Physicians. 2007 Feb; 53(2):45-6.
  138. Roy A, Roy V. Primary systemic amyloidosis. [Turkish]. SENDROM. 2007; 19(1):62-7.
  139. Lacy MQ, Dispenzieri A, Gertz MA, Greipp PR, Gollbach KL, Hayman SR, Kumar S, Lust JA, Rajkumar SV, Russell SJ, Witzig TE, Zeldenrust SR, Dingli D, Bergsagel PL, Fonseca R, Reeder CB, Stewart AK, Roy V, Dalton RJ, Carr AB, Kademani D, Keller EE, Viozzi CF, Kyle RA. Mayo clinic consensus statement for the use of bisphosphonates in multiple myeloma. Mayo Clin Proc. 2006 Aug; 81 (8):1047-53
    View PubMed
  140. Roy V, Perez EA. New therapies in the treatment of breast cancer. Semin Oncol. 2006 Jun; 33 (3 Suppl 9):S3-8
    View PubMed
  141. Valente M, Roy V, Lacy MQ, Dispenzieri A, Gertz MA. Autologous stem cell transplantation and IgM amyloidosis. Leuk Lymphoma. 2006 Jun; 47 (6):1006-12
    View PubMed
  142. Roy A, Roy V. Primary systemic amyloidosis. Early diagnosis and therapy can improve survival rates and quality of life. Postgrad Med. 2006 Jun-Jul; 119 (1):93-9
    View PubMed
  143. Sekhon SS, Roy V. Thrombocytopenia in adults: A practical approach to evaluation and management. South Med J. 2006 May; 99 (5):491-8; quiz 499-500, 533
    View PubMed
  144. Roy V, Perez EA. Adjuvant docetaxel plus doxorubicin and cyclophosphamide increases survival compared with fluorouracil plus doxorubicin and cyclophosphamide in women with operable node-positive breast cancer. Cancer Treat Rev. 2006 Feb; 32(1):55-8. Epub 2006 Jan 19.
    View PubMed
  145. Roy A, Roy V. Using beta-blocker to cut perioperative risk in CAD. [Turkish]. SENDROM. 2006; 18(12):42-5.
  146. Roy A, Heckman MG, Roy V. Associations between the hospitalist model of care and quality-of-care-related outcomes in patients undergoing hip fracture surgery. Mayo Clin Proc. 2006 Jan; 81 (1):28-31
    View PubMed
  147. Roy A, Roy V. Using beta-blockers to cut perioperative risk in CAD. Cardioprotective strategies for noncardiac surgery. Postgrad Med. 2005 Dec; 118 (6):34-6, 41-2
    View PubMed
  148. Roy A, Gisel JJ, Roy V, Bouras EP. Superior mesenteric artery (Wilkie's) syndrome as a result of cardiac cachexia. J Gen Intern Med. 2005 Oct; 20 (10):C3-4
    View PubMed
  149. Pavletic SZ, Khouri IF, Haagenson M, King RJ, Bierman PJ, Bishop MR, Carston M, Giralt S, Molina A, Copelan EA, Ringden O, Roy V, Ballen K, Adkins DR, McCarthy P, Weisdorf D, Montserrat E, Anasetti C. Unrelated donor marrow transplantation for B-Cell chronic lymphocytic leukemia after using myeloablative conditioning: Results from the center for international blood and marrow transplant research. J Clin Oncol. 2005 Aug 20; 23(24):5788-94.
    View PubMed
  150. Roy V, Perez WS, Eapen M, Marsh JCW, Pasquini M, Pasquini R, Mustafa MM, Bredeson CN. Bone marrow transplantation for Diamond-Blackfan anemia. Biol Blood Marrow Transplant. 2005 Aug; 11(8):600-8.
    View PubMed
  151. Dispenzieri A, Moreno-Aspitia A, Suarez GA, Lacy MQ, Colon-Otero G, Tefferi A, Litzow MR, Roy V, Hogan WJ, Kyle RA, Gertz MA. Peripheral blood stem cell transplantation in 16 patients with POEMS syndrome, and a review of the literature. Blood. 2004 Nov 15; 104 (10):3400-7 Epub 2004 July 27
    View PubMed
  152. Whitehead RP, Lew D, Flanigan RC, Weiss GR, Roy V, Glode ML, Dakhil SR, Crawford ED. Phase II trial of recombinant human interleukin-4 in patients with advanced renal cell carcinoma: a Southwest Oncology Group study. J Immunother. 2002 Jul-Aug; 25(4):352-8.
    View PubMed
  153. Flanigan RC, Salmon SE, Blumenstein BA, Bearman SI, Roy V, McGrath PC, Caton JR Jr, Munshi N, Crawford ED. Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. N Engl J Med. 2001 Dec 6; 345(23):1655-9.
    View PubMed
  154. Roy V, Rizvi MA, Vesely SK, George JN. Thrombotic thrombocytopenic purpura-like syndromes following bone marrow transplantation: an analysis of associated conditions and clinical outcomes. Bone Marrow Transplant. 2001 Mar; 27(6):641-6.
    View PubMed
  155. Petersdorf SH, Kopecky KJ, Head DR, Boldt DH, Balcerzak SP, Wun T, Roy V, Veith RW, Appelbaum FR. Comparison of the L10M consolidation regimen to an alternative regimen including escalating methotrexate/L-asparaginase for adult acute lymphoblastic leukemia: a Southwest Oncology Group Study. Leukemia. 2001 Feb; 15(2):208-16.
    View PubMed
  156. Roy V, Ali LI, Carter TH, Selby GB. Successful non-surgical treatment of disseminated polymicrobial fungal infection in a patient with pancytopenia and graft-versus-host disease. J Infect. 2000 Nov; 41(3):273-5.
    View PubMed
  157. Roy V, Ali LI, Selby GB. Routine chest radiography for the evaluation of febrile neutropenic patients after autologous stem cell transplantation. Am J Hematol. 2000 Jul; 64(3):170-4.
    View PubMed
  158. Fisher RI, Dana BW, LeBlanc M, Kjeldsberg C, Forman JD, Unger JM, Balcerzak SP, Gaynor ER, Roy V, Miller T. Interferon alpha consolidation after intensive chemotherapy does not prolong the progression-free survival of patients with low-grade non-Hodgkin's lymphoma: results of the Southwest Oncology Group randomized phase III study 8809. J Clin Oncol. 2000 May; 18(10):2010-6.
    View PubMed
  159. Abang AM, Takemoto MH, Pham T, Mandanas RA, Roy V, Selby GB, Carter TH. Efficacy and safety of oral granisetron versus i.v. granisetron in patients undergoing peripheral blood progenitor cell and bone marrow transplantation. Anticancer Drugs. 2000 Feb; 11(2):137-42.
    View PubMed
  160. Roy V, Verfaillie CM. Expression and function of cell adhesion molecules on fetal liver, cord blood and bone marrow hematopoietic progenitors: implications for anatomical localization and developmental stage specific regulation of hematopoiesis. Exp Hematol. 1999 Feb; 27(2):302-12.
    View PubMed
  161. Mandanas RA, Carter TH, Epstein RB, Roy V, Selby GB. Marrow and stem cell transplantation in Oklahoma: fifteen years of experience and results. J Okla State Med Assoc. 1998 Sep; 91(6):339-46.
    View PubMed
  162. Roy V, Verfaillie CM. Soluble factor(s) produced by adult bone marrow stroma inhibit in vitro proliferation and differentiation of fetal liver BFU-E by inducing apoptosis. J Clin Invest. 1997 Aug 15; 100(4):912-20.
    View PubMed
  163. Roy V, Ochs L, Weisdorf D. Late infections following allogeneic bone marrow transplantation: suggested strategies for prophylaxis. Leukemia & Lymphoma. 1997 Jun; 26(1-2):1-15.
    View PubMed
  164. Roy V, Miller JS, Verfaillie CM. Phenotypic and functional characterization of committed and primitive myeloid and lymphoid hematopoietic precursors in human fetal liver. Exp Hematol. 1997 May; 25(5):387-94.
    View PubMed
  165. Roy V, Weisdorf D. Mycobacterial infections following bone marrow transplantation: a 20 year retrospective review. Bone Marrow Transplant. 1997 Mar; 19(5):467-70.
    View PubMed
  166. Verfaillie CM, Bhatia R, Miller W, Mortari F, Roy V, Burger S, McCullough J, Stieglbauer K, Dewald G, Heimfeld S, Miller JS, McGlave PB. BCR/ABL-negative primitive progenitors suitable for transplantation can be selected from the marrow of most early-chronic phase but not accelerated-phase chronic myelogenous leukemia patients. Blood. 1996 Jun 1; 87(11):4770-9.
    View PubMed
  167. Roy V, Verfaillie CM. Refractory thrombocytopenia due to anti-PLA1 antibodies following autologous peripheral blood stem cell transplantation: case report and review of literature. Bone Marrow Transplant. 1996 Jan; 17(1):115-7.
    View PubMed
  168. Roy V, Veys P, Jackson F, Ryan J, Lowdell M, Newland AC. Adult respiratory syndrome following autologous bone marrow transfusion. Bone Marrow Transplant. 1989 Nov; 4(6):711-2.
    View PubMed
  169. Roy V, Gutteridge CN, Nysenbaum A, Newland AC. Combination chemotherapy with conservative obstetric management in the treatment of pregnant patients with acute myeloblastic leukaemia. Clinical & Laboratory Haematology. 1989; 11(3):171-8.
    View PubMed
  170. Roy V, Tillyer ML, Colvin BT. Acute abdominal pain due to an acquired disorder of coagulation. Br Med J (Clin Res Ed). 1988 May 21; 296: (6634)1460.
    View PubMed